Using differential signals in data-acquisition systems is becoming increasingly popular because differential signals are highly immune to system noise based on the common-mode rejection of a ...
James Sillibourne (below) is Director of Synthetic Genomics at Autolus Therapeutics (London, UK), a biotech company focussing on developing chimeric antigen-receptor T-cell (CAR-T) therapies for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback